Exploring the novel combinations of immunotherapies for the treatment of lung cancer
Lead Research Organisation:
Queen Mary University of London
Department Name: William Harvey Research Institute
Abstract
Our preliminary results have shown a 30-40% reduction in tumour volume in KRAS driven lung tumours when treated with Acalabrutinib. In this study, we aim to explore the therapeutic effect of Acalabrutinib when combined with STAT3 inhibition in the hope to achieve a better treatment response. The first step of this project is to treat with Acalabrutinib, STAT3 inhibitor and STAT3 inhibitor when combined with Acalabrutinib in vivo. In parallel, a panel of 32 human cancer cell lines will be assessed for the expression and activation of STAT3 and the drug target of Acalabrutinib, Bruton Tyrosine (BTK). The tumour microenvironment will also be characterized in vivo with a special focus on immune populations and their phenotypes.
Skills Priority Alignment: Advanced Therapeutics, Quantitative Biology, Whole Organism
Skills Priority Alignment: Advanced Therapeutics, Quantitative Biology, Whole Organism
People |
ORCID iD |
| Dianne Cooper (Primary Supervisor) | |
| Priyankaa Goordyal (Student) |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| MR/R502261/1 | 01/10/2017 | 30/09/2022 | |||
| 1954990 | Studentship | MR/R502261/1 | 01/10/2017 | 31/03/2021 | Priyankaa Goordyal |